Company
Genoss
Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
18
510(k), De Novo and PMA
Device trials
10
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 19, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
From SEC filings.
We found no SEC financing filings under the name Genoss, so its financing is unknown here. That is common for companies based outside the US, for subsidiaries of larger companies, and for companies funded by founders, grants or customers. A company that changed its name can also be missed.
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Genoss.
Latest FDA decisions
The 8 newest of 18 since 2015.
- Bluemoon510(k)
K242386 · Decided May 5, 2025 · 266 days after receipt
Device type: Activator, Ultraviolet, For Polymerization (EBZ) · Dentistry & Oral Surgery
- The Trust510(k)
K222688 · Decided Aug 9, 2024 · 703 days after receipt
Device type: Handpiece, Direct Drive, Ac-Powered (EKX) · Dentistry & Oral Surgery
- rainbow Paste Stain SE510(k)
K233885 · Decided Jun 21, 2024 · 196 days after receipt
Device type: Powder, Porcelain (EIH) · Dentistry & Oral Surgery
15 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
- Clinical Impact of DCB-based Versus DES-based Intervention in Patients With MVCADPivotal-lookingRecruiting
NCT07539324 · 892 participants (planned) · Start Sep 28, 2026 · Primary completion Dec 31, 2030
Device: GENOSS® DCB (Paclitaxel-coated PTCA balloon catheter); Contemporary Drug-Eluting Stents (DES) · For: Multi Vessel Coronary Artery Disease; Percutaneous Coronary Intervention
Sites: Ulsan, South Korea
- Efficacy and Safety of GENOSS® SES in Patients With Acute Coronary Syndrome (GENOSS ACS)Active, not recruiting
NCT06075368 · 757 participants · Start Mar 16, 2020 · Primary completion Dec 31, 2025
Device: GENOSS Sirolimus Eluting Coronary Stent System · For: Acute Coronary Syndrome; Percutaneous Coronary Intervention
Sites: Seongnam-si, South Korea
- Safety and Effectiveness of GENOSS® DES in Patients With Multivessel Coronary Artery DiseaseEnrolling by invitation
NCT06168305 · 1,000 participants (planned) · Start Nov 15, 2023 · Primary completion Feb 28, 2028
Device: GENOSS® DES Sirolimus Eluting Coronary Stent System · For: Percutaneous Coronary Intervention; Multivessel Coronary Artery Disease
Sites: Seoul, South Korea
7 more trials with a free account
Reports received
0
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.